Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan

被引：1

作者：

Yang, Chun-Chi ^{[1
]}

Huang, Chung-Feng ^{[2
,3
,4
]}

Chang, Te-Sheng ^{[5
,6
]}

Lo, Ching-Chu ^{[7
]}

Hung, Chao-Hung ^{[8
]}

Huang, Chien-Wei ^{[9
]}

Chong, Lee-Won ^{[10
,11
]}

Cheng, Pin-Nan ^{[12
,13
]}

Yeh, Ming-Lun ^{[2
,3
,14
]}

Peng, Cheng-Yuan ^{[15
,16
]}

Cheng, Chien-Yu ^{[17
]}

Huang, Jee-Fu ^{[2
,3
,14
,18
,19
,20
]}

Bair, Ming-Jong ^{[21
,22
]}

Lin, Chih-Lang ^{[23
,24
]}

Yang, Chi-Chieh ^{[25
]}

Wang, Szu-Jen ^{[26
]}

Hsieh, Tsai-Yuan ^{[27
]}

Lee, Tzong-Hsi ^{[28
]}

Lee, Pei-Lun ^{[29
]}

Wu, Wen-Chih ^{[30
]}

Lin, Chih-Lin ^{[31
]}

Su, Wei-Wen ^{[32
]}

Yang, Sheng-Shun ^{[33
]}

Wang, Chia-Chi ^{[34
,35
]}

Hu, Jui-Ting ^{[36
]}

Mo, Lein-Ray ^{[37
]}

Chen, Chun-Ting ^{[27
,38
]}

Huang, Yi-Hsiang ^{[39
,40
,41
]}

Chang, Chun-Chao ^{[42
,43
]}

Huang, Chia-Sheng ^{[44
]}

Chen, Guei-Ying ^{[45
]}

Kao, Chien-Neng ^{[46
]}

Tai, Chi-Ming ^{[47
,48
]}

Liu, Chun-Jen ^{[49
]}

Lee, Mei-Hsuan ^{[50
]}

Kuo, Hsing-Tao ^{[1
]}

Tsai, Pei-Chien ^{[2
,3
,14
]}

Dai, Chia-Yen ^{[2
,3
,14
]}

Kao, Jia-Horng ^{[49
]}

Lin, Han-Chieh ^{[39
,40
,41
]}

Chuang, Wang-Long ^{[2
,3
]}

Tseng, Kuo-Chih ^{[51
,52
]}

Chen, Chi-Yi ^{[53
]}

Yu, Ming-Lung ^{[2
,3
,8
,14
,18
,19
,20
]}

机构：

[1] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, 100,Tzyou 1st Rd, Kaohsiung, Taiwan

[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatitis Ctr, 100,Tzyou 1st Rd, Kaohsiung, Taiwan

[4] Kaohsiung Med Univ, Coll Med, PhD Program Translat Med, Acad Sinica, Kaohsiung, Taiwan

[5] ChiaYi Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Chiayi, Taiwan

[6] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[7] St Martin De Porres Hosp, Dept Internal Med, Div Gastroenterol, Chiayi, Taiwan

[8] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan

[9] Kaohsiung Armed Forces Gen Hosp, Dept Gastroenterol, Kaohsiung, Taiwan

[10] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan

[11] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Hepatol & Gastroenterol, Taipei, Taiwan

[12] Natl Cheng Kung Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[13] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan

[14] Kaohsiung Med Univ, Hepatitis Res Ctr, Coll Med, Ctr Liquid Biopsy & Cohort Res, Kaohsiung, Taiwan

[15] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, Taichung, Taiwan

[16] China Med Univ, Sch Med, Taichung, Taiwan

[17] Taoyuan Gen Hosp, Div Infect Dis, Dept Internal Med, Minist Hlth & Welf, Taoyuan, Taiwan

[18] Natl Sun Yat Sen Univ, Sch Med, Kaohsiung, Taiwan

[19] Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan

[20] Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis, Kaohsiung, Taiwan

[21] Taitung Mackay Mem Hosp, Dept Internal Med, Div Gastroenterol, Taitung, Taiwan

[22] Mackay Med Coll, New Taipei City, Taiwan

[23] Chang Gung Univ, Liver Res Unit, Dept Hepatogastroenterol, Chang Gung Mem Hosp Keelung,Coll Med, Keelung, Taiwan

[24] Chang Gung Univ, Chang Gung Mem Hosp Keelung, Coll Med, Community Med Res Ctr, Keelung, Taiwan

[25] Show Chwan Mem Hosp, Dept Gastroenterol, Div Internal Med, Changhua, Taiwan

[26] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[27] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[28] Far Eastern Mem Hosp, Div Gastroenterol, New Taipei City, Taiwan

[29] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[30] Wen Chih Wu Clin, Kaohsiung, Taiwan

[31] Taipei City Hosp, Renai Branch, Dept Gastroenterol, Taipei, Taiwan

[32] Changhua Christian Hosp, Dept Gastroenterol & Hepatol, Changhua, Taiwan

[33] Taichung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung, Taiwan

[34] Tzu Chi Univ, Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Taipei, Taiwan

[35] Tzu Chi Univ, Taipei Tzu Chi Hosp, Sch Med, Taipei, Taiwan

[36] Cathay Gen Hosp, Liver Ctr, Taipei, Taiwan

[37] Tainan Municipal Hosp, Div Gastroenterol, Show Chwan Med Care Corp, Tainan, Taiwan

[38] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Gastroenterol,Penghu Branch, Taipei, Taiwan

[39] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[40] Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan

[41] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Coll Med, Taipei, Taiwan

[42] Taipei Med Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[43] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Gastroenterol & Hepatol, Taipei, Taiwan

[44] Yang Ming Hosp, Chiayi, Taiwan

[45] Penghu Hosp, Minist Hlth & Welf, Penghu, Taiwan

[46] Natl Taiwan Univ Hosp, Hsin Chu Branch, Hsinchu, Taiwan

[47] I Shou Univ, E Da Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Kaohsiung, Taiwan

[48] I Shou Univ, Coll Med, Sch Med Int Students, Kaohsiung, Taiwan

[49] Natl Taiwan Univ Hosp, Dept Internal Med, Hepatitis Res Ctr, Taipei, Taiwan

[50] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan

来源：

INFECTIOUS DISEASES AND THERAPY | 2024年 / 13卷 / 06期

关键词：

Hepatitis C; Direct-acting antivirals; Glecaprevir; Pibrentasvir; Real world; Taiwan;

D O I：

10.1007/s40121-024-00968-5

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction Eight-week glecaprevir/pibrentasvir (GLE/PIB) is indicated for treatment-na & iuml;ve (TN) patients with chronic hepatitis C (CHC), with or without compensated cirrhosis. Given that the Taiwanese government is committed to eliminating hepatitis C virus (HCV) by 2025, this study aimed to measure real-world evidence for TN patients using 8-week GLE/PIB in the Taiwan HCV Registry (TACR).Methods The data of patients with CHC treated with 8-week GLE/PIB were retrieved from TACR, a nationwide registry program organized by the Taiwan Association for the Study of the Liver (TASL). Treatment efficacy, defined as a sustained virologic response at posttreatment week 12 (SVR12), was assessed in the modified intention-to-treat (mITT) population, which excluded patients who were lost to follow-up or lacked SVR12 data. The safety profile of the ITT population was assessed.Results A total of 7246 (6897 without cirrhosis; 349 with cirrhosis) patients received at least one dose of GLE/PIB (ITT), 7204 of whom had SVR12 data available (mITT). The overall SVR12 rate was 98.9% (7122/7204) among all patients, 98.9% (6780/6856) and 98.3% (342/348) among patients without and with cirrhosis, respectively. For the selected subgroups, which included patients with genotype 3 infection, diabetes, chronic kidney disease, people who injected drugs, and those with human immunodeficiency virus coinfection, the SVR12 rates were 95.1% (272/286), 98.9% (1084/1096), 99.0% (1171/1183), 97.4% (566/581), and 96.1% (248/258), respectively. Overall, 14.1% (1021/7246) of the patients experienced adverse events (AEs). Twenty-two patients (0.3%) experienced serious AEs, and 15 events (0.2%) resulted in permanent drug discontinuation. Only one event was considered treatment drug related.Conclusion Eight-week GLE/PIB therapy was effective and well tolerated in all TN patients, regardless of cirrhosis status.

引用

页码：1199 / 1213

页数：15

共 50 条

[21] Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
Yamana, Yoichiro
Kanda, Tatsuo
Matsumoto, Naoki
Honda, Masayuki
Kumagawa, Mariko
Sasaki, Reina
Kanezawa, Shini
Mizutani, Taku
Yamagami, Hiroaki
Masuzaki, Ryota
Ishii, Tomotaka
Nirei, Kazushige
Moriyama, Mitsuhiko
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
[22] Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
Huff, Jamie
Andersen, Rebecca
ANNALS OF PHARMACOTHERAPY, 2020, 54 (03) : 262 - 276
[23] EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH ACUTE HEPATITIS C: A SINGLE-ARM RETROSPECTIVE STUDY
Pol, Stanislas
Thompson, Alexander J.
Collins, Michelle
Venier, Elisa
Cotte, Laurent
Laguno, Monserrat
Mera, Jorge Raul
Reiberger, Thomas
Burroughs, Margaret
Semizarov, Dimitri G.
Iacob, Alexandru M.
Welhaven, Anne
Fredrick, Linda
Doyle, Joseph S.
HEPATOLOGY, 2024, 79 (02) : E81 - E82
[24] Efficacy of Real-world Entecavir Therapy in Treatment-na?ve Chronic Hepatitis B Patients
Xie Yan-Di
Ma Hui
Feng Bo
Wei Lai
中华医学杂志英文版, 2017, 130 (18) : 2190 - 2197
[25] Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study
Brown, Robert S., Jr.
Hezode, Christophe
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto I.
Horvath, Gabor
Rosado-Carrion, Barbara
Rodriguez-Perez, Federico
Cohen, Eric
Hui, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino, Jr.
Trinh, Roger
Mensa, Federico J.
Felizarta, Franco
HEPATOLOGY, 2018, 68 : 425A - 426A
[26] Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study
Pawlowska, Malgorzata
Dobrowolska, Krystyna
Moppert, Justyna
Pokorska-Spiewak, Maria
Purzynska, Mariola
Marczynska, Magdalena
Zarebska-Michaluk, Dorota
Flisiak, Robert
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
[27] Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load
Wu, Xue
Yan, Qin
Jiang, Chunmei
Fan, Rongshan
Li, Sheling
SCIENTIFIC REPORTS, 2024, 14 (01):
[28] Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
Liu, Chen-Hua
Liu, Chun-Jen
Hung, Chien-Ching
Hsieh, Szu-Min
Su, Tung-Hung
Sun, Hsin-Yun
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng
LIVER INTERNATIONAL, 2020, 40 (04) : 758 - 768
[29] PRELIMINARY EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 1-6 INFECTION AND COMPENSATED CIRRHOSIS: THE EXPEDITION-8 STUDY
Brown, Robert S., Jr.
Hezode, Christopher
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto
Horvath, Gabor
Carrion, Barbara Rosado
Rodriguez-Perez, Federico
Cohen, Eric
Hu, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino
Trinh, Roger
Mensa, Federico J.
GUT, 2019, 68 : A146 - A146
[30] Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study
Brown, Robert S., Jr.
Hezode, Christophe
Wang, Stanley
Buti, Maria
Chuang, Wan-Long
Aguilar, Humberto I.
Horvath, Gabor
Rosado-Carrion, Barbara
Rodriguez-Perez, Federico
Cohen, Eric
Hu, Yiran B.
Schnell, Gretja
Lin, Chih-Wei
Rodrigues, Lino, Jr.
Trinh, Roger
Mensa, Federico J.
Felizarta, Franco
HEPATOLOGY, 2018, 68 (06) : 1450A - 1451A

← 1 2 3 4 5 →